Risperdal Consta

Irritability, Autism, Schizophrenia + 10 more

Treatment

6 FDA approvals

20 Active Studies for Risperdal Consta

What is Risperdal Consta

Risperidone

The Generic name of this drug

Treatment Summary

Risperidone is a medication used to treat schizophrenia, bipolar disorder, and other mood disorders. It works by blocking certain receptors in the brain, including dopamine and serotonin receptors, which helps to reduce the excessive activity of certain pathways in the brain that are believed to cause these disorders. Risperidone is one of the most commonly used second-generation antipsychotics and has a very high affinity for serotonin receptors, which makes it more effective at treating symptoms than other medications.

Risperidone

is the brand name

image of different drug pills on a surface

Risperdal Consta Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Risperidone

Risperidone

1993

522

Approved as Treatment by the FDA

Risperidone, also known as Risperidone, is approved by the FDA for 6 uses such as Bipolar 1 Disorder and Acute Mania .

Bipolar 1 Disorder

Acute Mania

Mixed manic depressive episode

Common Cold

Bipolar Disorder

Bipolar Disorder

Effectiveness

How Risperdal Consta Affects Patients

Risperidone works by decreasing activity in the pathways related to dopamine and serotonin in the brain. This helps reduce the symptoms of schizophrenia and other mood disorders. Risperidone binds more strongly to serotonin receptors than dopamine receptors. It has a lower binding affinity for dopamine receptors than earlier drugs, which may explain why it causes fewer side effects related to movement.

How Risperdal Consta works in the body

Risperidone works by temporarily blocking dopamine and serotonin receptors in the brain. This helps reduce the positive symptoms of schizophrenia, such as delusions and hallucinations. It also reduces the negative symptoms, like depression and decreased motivation, by blocking serotonin receptors. Risperidone also blocks alpha-1, alpha-2 and histamine receptors, though we don't completely understand how this improves symptoms of schizophrenia. By doing all of the above, risperidone reduces the risk of side effects like extrapyramidal symptoms.

When to interrupt dosage

The measure of Risperdal Consta is contingent upon the determined condition, including Psychotic Disorders, Irritability and Acute Mania. The dosage fluctuates as indicated by the technique of delivery (e.g. Subcutaneous or Solution) featured in the table beneath.

Condition

Dosage

Administration

Autism

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Schizophrenia

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Acute Coryza

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Schizophrenia

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Bipolar Disorder

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Behcet Syndrome

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Alzheimer's Disease

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Common Cold

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Schizophrenia

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

responsive to first treatment

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Irritability

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Psychotic Disorders

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Bipolar Disorder

, 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg, 3.0 mg, 0.25 mg, 1.0 mg/mL, 25.0 mg, 37.5 mg, 50.0 mg, 12.5 mg, 5.0 mg, 12.5 mg/mL, 37.5 mg/mL, 50.0 mg/mL, 25.0 mg/mL, 900.0 mg/mL, 1200.0 mg/mL, 120.0 mg, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit, Kit - Subcutaneous, Subcutaneous, Kit; Powder, for suspension, Kit; Powder, for suspension - Subcutaneous, Injection, powder, for suspension, extended release; Kit - Subcutaneous

Warnings

Risperdal Consta Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Risperidone may interact with Pulse Frequency

There are 20 known major drug interactions with Risperdal Consta.

Common Risperdal Consta Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alfuzosin

Major

Risperidone may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Risperidone may increase the antipsychotic activities of Amisulpride.

Aripiprazole

Major

Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Aripiprazole lauroxil

Major

Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Risperdal Consta Toxicity & Overdose Risk

Overdosing on Haloperidol can cause drowsiness, muscle spasms, rapid heartbeat, slow heartbeat and seizures. The lowest lethal dose in rats is 57.7 mg/kg when taken orally and 34 mg/kg when injected intravenously.

image of a doctor in a lab doing drug, clinical research

Risperdal Consta Novel Uses: Which Conditions Have a Clinical Trial Featuring Risperdal Consta?

359 active studies are currently evaluating the potential of Risperdal Consta to mitigate Acute Mania, Bipolar Disorder and Autism.

Condition

Clinical Trials

Trial Phases

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Schizophrenia

32 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Schizophrenia

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Irritability

8 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Psychotic Disorders

0 Actively Recruiting

Acute Coryza

1 Actively Recruiting

Not Applicable

Common Cold

0 Actively Recruiting

Autism

7 Actively Recruiting

Phase 2, Not Applicable

Bipolar Disorder

0 Actively Recruiting

Alzheimer's Disease

15 Actively Recruiting

Not Applicable, Phase 2, Phase 1

responsive to first treatment

0 Actively Recruiting

Risperdal Consta Reviews: What are patients saying about Risperdal Consta?

4.3

Patient Review

2/23/2013

Risperdal Consta for Schizophrenia

On behalf of my son, who died by suicide after 3 attempts, I want to warn others about the risks associated with Risperdal Consta injections.

3

Patient Review

6/29/2015

Risperdal Consta for Schizophrenia

One downside to this medication is that it caused weight gain in my son. He ended up in the hospital for nine days as a result of vomiting, excessive thirst, and sleepiness. Doctors discovered upon his arrival that he had high blood sugar levels (nearly 467).

2.7

Patient Review

5/26/2015

Risperdal Consta for Schizophrenia

I'm new to this drug, and so far I like it. However, I can see why some people wouldn't recommend it based on how painful it is to administer. It burns and you can hardly move your arm or hand afterwards.

2

Patient Review

3/5/2014

Risperdal Consta for Bipolar Disorder in Remission

Risperdal Consta has been very beneficial for me in terms of keeping my mood and behavior stable. I preferred it to the oral version of the medication, and would highly recommend it to others.

2

Patient Review

9/6/2012

Risperdal Consta for Schizophrenia

I'm struggling to afford this medication for my son. It's been helping him, so I hope we can find a way to keep paying for it.

1.7

Patient Review

7/22/2014

Risperdal Consta for Bipolar Disorder in Remission

I've taken Risperdal injections for 4 months for Bipolar. It makes my concentration poor and I feel dead and in limbo.

1.7

Patient Review

9/6/2018

Risperdal Consta for Schizophrenia

This drug made me feel awful. I couldn't get up or do anything, my speech was slurred, and it felt like it half-destroyed my brain. I used to be in great shape, but now I've gained twenty pounds. If given the choice, I would rather be slightly deranged than have to take this medication, but unfortunately society has forced me into this position.

1.3

Patient Review

4/1/2015

Risperdal Consta for Manic-Depression

I've been on this for five months and it's done nothing but make me suffer. I've gained weight, lost my sex drive, and can't sleep. My psychiatrist won't let me stop taking it even though it's clearly not working.

1

Patient Review

11/26/2011

Risperdal Consta for Schizophrenia

1

Patient Review

11/27/2011

Risperdal Consta for Schizophrenia

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about risperdal consta

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is RISPERDAL CONSTA injection?

"This medication is indicated to be used either on its own or alongside lithium or valproate in order to maintain treatment for Bipolar I Disorder, or to treat schizophrenia."

Answered by AI

How often is RISPERDAL CONSTA given?

"For gluteal administration, use the 1.5-inch needle. Cleanse the top of the vial with an alcohol swab. Remove the cap from the vial adapter and insert it into the vial.

The drugs RISPERDAL CONSTA should be given every two weeks by a deep intramuscular injection either into the deltoid muscle of the shoulder or into the gluteal muscle of the buttocks, using the safety needles provided. If you are injecting into the deltoid muscle, use the 1-inch needle and alternate between injecting into the two arms. If you are injecting into the gluteal muscle, use the 1.5-inch needle. Before you start, clean the top of the vial with an alcohol swab. Remove the cap from the vial adapter and insert it into the vial."

Answered by AI

Can RISPERDAL CONSTA be given monthly?

"You can gradually increase the dosage of risperidone-SQ over time until you reach a monthly dose of either 90 mg or 120 mg, depending on what is tolerable for you."

Answered by AI

What is the difference between Risperdal and RISPERDAL CONSTA?

"The drugs Risperdal and Risperdal Consta are both antipsychotic drugs prescribed to treat schizophrenia, bipolar mania, and autism. Risperdal Consta is an injectable, long-acting form of risperidone."

Answered by AI

Clinical Trials for Risperdal Consta

Have you considered Risperdal Consta clinical trials?

We made a collection of clinical trials featuring Risperdal Consta, we think they might fit your search criteria.
Go to Trials
Image of Wellstar MCG Hospital, Neurology Memory Clinic in Augusta, United States.

Deep Brain Stimulation for Alzheimer's Disease

65 - 85
All Sexes
Augusta, GA

The purpose of this study is to test a new procedure to treat Alzheimer's disease. The procedure is called intermittent Deep Brain Stimulation (DBS) of the nucleus basalis of Meynert. There will be up to six participants enrolled at Wellstar MCG Memory Clinic. There will be another six participants similarly enrolled to act as a control group that does not receive DBS. This second group will document the course of progression of Alzheimer's disease under the normal standard of care. The main goal of the study is to determine if DBS can sustain or improve cognition in Alzheimer's disease for at least two years. Participant data, with identifying information removed, may be shared with online repositories for comparison with trials with similar subjects.

Phase 1
Recruiting

Wellstar MCG Hospital, Neurology Memory Clinic

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Multimodal Intervention for Bipolar Disorder

18 - 35
All Sexes
Hamilton, Canada

People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.

Recruiting
Has No Placebo

St. Joseph's Healthcare Hamilton

Have you considered Risperdal Consta clinical trials?

We made a collection of clinical trials featuring Risperdal Consta, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN

The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.

Waitlist Available
Has No Placebo

Vanderbilt Psychiatric Hospital

Heather Ward, MD

Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Phase 2
Recruiting

Woodland International Research Group /ID# 275747 (+6 Sites)

ABBVIE INC.

AbbVie

Have you considered Risperdal Consta clinical trials?

We made a collection of clinical trials featuring Risperdal Consta, we think they might fit your search criteria.
Go to Trials